Reversing bacterial resistance with accelerated assay development
A new automated method for high-dimensional assay development is enabling researchers to rapidly identify drug candidates targeting bacterial resistance mechanisms. This advancement, made possible through a collaboration between the University of Oxford, JMP, and Synthace, focuses on the RecBCD enzyme and marks a significant step forward for drug discovery in the fight against antibiotic-resistant bacteria.
Adam Winnifrith
University of Oxford
Markus Gershater
CEO & Co-Founder, Synthace
To read more about the research discussed in this video, please see the RSC Chemical Biology paper.
Adam Winnifrith, Steven R. Brown, Piotr Jedryszek, C. Grant, Philip E. Kay, Adam M. Thomas, Jacob D. Bradbury and Thomas Lanyon-Hogg. Development of a fluorescence-based assay for RecBCD activity using functional data analysis and design of experiments. RSC Chemical Biology: DOI: 10.1039/d4cb00291a